18
Participants
Start Date
July 22, 2013
Primary Completion Date
March 19, 2019
Study Completion Date
October 7, 2019
Anakinra
An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If active disease persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4 and 300mg/day at week 8.
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH